Compare C.H. Robinson Worldwide, Inc. (CHRW) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C.H. Robinson Worldwide, Inc. vs Novartis AG — how do they compare? C.H. Robinson Worldwide, Inc. trades at $147.73 (market cap $16.96B), while Novartis AG trades at $152.74 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.4× C.H. Robinson Worldwide, Inc.'s market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| CHRW | NVS | |
|---|---|---|
Market Cap | $16.96B | $295.37B |
Sector | Industrials | Health |
52-Week High | $209.42 | $168.62 |
52-Week Low | $118.77 | $119.31 |
Enterprise Value | $18.78B | $336.69B |
Dividend Yield | 1.74% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $147.68, down 0.41% with bearish technical signals, though recent earnings beats and strong profitability metrics provide fundamental support. The company reported Q2 2026 EPS of $1.61, beating expectations, with revenue of $16.23B in 2025 and net income margin improving to 3.73%. Analyst consensus remains positive with a $193 price target, while recent news highlights dividend declarations and institutional buying activity.
Outlook remains cautiously optimistic given earnings momentum and solid ROE of 37.12%, though technical weakness and legal challenges pose near-term risks. The stock offers growth potential with reasonable valuation (P/E 27.7) but faces headwinds from freight demand volatility and competitive pressures in logistics.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
